Journal article
EGFR mutations in malignant pleural effusions from lung cancer
Current pulmonology reports, Vol.2(2), pp.79-87
06/01/2013
DOI: 10.1007/s13665-013-0041-5
Abstract
A malignant pleural effusion (MPE) from lung cancer represents stage IV disease and portends a poor prognosis. Routine mutational analysis of tissue samples is the standard of care in advanced lung cancer management because it has treatment implications. Sampling of MPE is minimally invasive, safe, repeatable, and provides both diagnostic and therapeutic value. Mutational analysis on MPE has been shown to be feasible and correlates with a response to targeted therapy with tyrosine kinase inhibitors (TKIs). Guidelines recommend mutational testing in MPE, however there is no one standardized method for testing. There are several testing methods available for mutational analysis in pleural fluid including PCR, mutant-enriched PCR, DNA & RNA sequencing, and immunohistochemistry the sensitivity of which are dependent upon tumor cell heterogeneity. The advantages and disadvantages of each will be reviewed here.
Details
- Title: Subtitle
- EGFR mutations in malignant pleural effusions from lung cancer
- Creators
- Clayton J. Shamblin - Medical University of South CarolinaNichole T. Tanner - Medical University of South CarolinaRolando Sanchez Sanchez - Medical University of South CarolinaJulie A. Woolworth - Medical University of South CarolinaGerard A. Silvestri - Medical University of South Carolina
- Resource Type
- Journal article
- Publication Details
- Current pulmonology reports, Vol.2(2), pp.79-87
- Publisher
- Springer Nature
- DOI
- 10.1007/s13665-013-0041-5
- ISSN
- 2161-332X
- eISSN
- 2199-2428
- Number of pages
- 9
- Language
- English
- Date published
- 06/01/2013
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
- Record Identifier
- 9984363295402771
Metrics
2 Record Views